Cardiovascular & Metabolic Disorders
Investigators examined gender differences in baseline characteristics and outcomes in patients with t2d and ASCVD.
The relationship between circadian rhythm and sleep measures and components of metabolic syndrome in patients with bipolar disorder.
Older adults with metabolic syndrome experienced higher rates of depressive symptoms compared with older adults without metabolic syndrome.
Investigators revised pooled cohort equations to improve clinical accuracy to predict risk for cardiovascular disease.
Investigators examine the effects of the PCSK9 inhibitor alirocumab in patients with recent acute coronary syndrome and diabetes.
Investigators examined cardiovascular outcomes in patients with elevated triglyceridemia and diabetes treated with statins.
These results support the need to assess the role of sleep quantity and quality interventions as strategies for improving cardiovascular risk profiles of adolescents.
Researchers assessed the effect of testosterone, estradiol, dehydroepiandrosterone, and sex hormone-binding globulin levels on coronary heart disease, heart failure, and cardiovascular disease in postmenopausal women.
To understand the mechanism underlying the benefit of fenofibrate on vascular complications in patients with type 2 diabetes, investigators assessed carotid intima thickness as a marker of subclinical atherosclerosis.
Regardless of long-term metabolic health maintenance, obesity remains a risk factor for cardiovascular disease.
Investigators sought to assess the link between treatment for thyroid cancer and subsequent cardiac and vascular complications.
Investigators sought to determine whether serum lipid levels were associated with depression in patients with psychotic disorders.
Investigators examined the effect of progestin-only contraceptive on cardiometabolic outcomes, including stroke, MI, hypertension, diabetes, and VTE.
Improved calculations suggest major changes to statin, aspirin, and blood pressure medication prescribingJune 06, 2018
Updated risk calculations suggest that fewer people should be classified within the high-risk category for CVD.
Fewer Major Adverse Cardiovascular Events With New Antihyperglycemic Drugs With Lower Hypoglycemic RiskMay 31, 2018
Investigators proposed that reduction in MACE may be proportional to the magnitude of HbA1c reduction seen with newer antihyperglycemic agents.
In this systematic review and meta-analysis, more intensive compared with less itensive LDL-C lowering was associated with a greater reduction in risk of total and cardiovascular mortality in trials of patients with higher baseline LDL-C levels.
Further studies are needed to assess whether beta-blockers are effective in reducing mortality and coronary events in patients with diabetes receiving optimal medical treatment.
Early treatment of cardiovascular disease risk factors such as dyslipidemia and hypertension will have long-term benefits with low risk and cost and should be more widely used in pediatric type 1 diabetes care.
Researchers assessed differences in glycemic control, major cardiovascular risk factors, diabetes-related complications, sexual dysfunction prevalence, and endothelial function in young men and women with type 1 diabetes.
Results provide critical perspective on cardiovascular disease associated with overweight and obesity and challenge both the obesity paradox as well as the view that overweight is associated with greater longevity.
Study found that the absence of proliferative diabetic retinopathy in those with stage 3b chronic kidney disease is associated with a lower prevalence of cardiovascular disease in patients with long duration of type 1 diabetes.
Abnormal glucose metabolism was detected in 1 out of 3 patients with nondiabetic percutaneous coronary intervention and was independently associated with a significantly higher event risk.
Study examined the association between individual antidiabetic sulfonylureas and outpatient-originating sudden cardiac arrest and ventricular arrhythmia.
Increases in waist circumference and waist-to-hip ratio are associated with a greater excess risk of myocardial infarction in women than men.
The method of individualized treatment effect prediction of fenofibrate on major cardiovascular events risk reduction in T2D can be used to guide clinical decision-making.
The acute-to-chronic glycemic ratio provided better prognostic insight with regard to in-hospital mortality and morbidity outcomes compared with glycemia levels at hospital admission in patients with diabetes who had an acute myocardial infarction.
Prior authorization requirements are greater for proprotein convertase subtilisin/kexin type 9 inhibitors than for other cardiometabolic drugs.
A patient living near an area experiencing frequent wildfires is concerned about the potential negative effect that the wildfires may have on his health.
The novel findings in this study suggest that patients with type 2 diabetes have a significantly reduced risk for short-term mortality after hospitalization for aortic aneurysm compared with population-based control subjects.
Abatacept conferred a greater reduction in cardiovascular risk compared with tumor necrosis factor inhibitors in patients with rheumatoid arthritis and diabetes.
Endocrinology Advisor Articles
- Two Phases of C-Peptide Decline Identified in Type I Diabetes
- Dulaglutide Effective for Patients With T2D, Moderate to Severe CKD
- Incidence of Diabetes Influenced by Endocrine-Disrupting Chemicals in the Environment
- Guidelines for Management of Hypothalamic-Pituitary, Growth Disorders in Childhood Cancer Survivors
- Assessment of Low-Dose Aspirin As Chemoprevention in Type 2 Diabetes
- Using Latent Class Trajectory Analysis to Determine Glucose Response Curve Patterns
- First CGM System With Implantable Glucose Sensor Approved
- Adjunctive Metformin for Insulin Resistance in T1D: A Clinical Perspective
- Risk for Below Knee Amputations With Canagliflozin vs Other Antihyperglycemic Agents
- Empagliflozin, Linagliptin Combination Therapy vs Linagliptin Monotherapy for Type 2 Diabetes
- Government and Industry Lead the Way in Funding USPSTF Systematic Reviews
- New Romosozumab BLA Includes Data from Additional Osteoporosis Trials
- Impact of Maternal Diabetes on Outcomes in Very Preterm, Very Low-Birth-Weight Infants
- Age-Related Differences in Manifestation of Cushing Disease Identified
- International Group Develops Best Practices for Drug Packaging